Skip to content

effect of Irsa(Iris Germanica L.) topical product on melasma

Evaluating the effect of Irsa(Iris Germanica L.) topical product on melasma

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230729058956N1
Enrollment
66
Registered
2023-10-24
Start date
2023-09-23
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: "Intervention group": includes people who receive Irsa cream. For 12 weeks, a thin layer of cream is applied on the spots in the morning and at night, and sunscreen is used during the

Sponsors

Shahed University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Women aged 18-60 years Having clear lesions of melasma with expert approval

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Local or systemic treatment of melasma in the last 4 weeks Use of hormonal drugs (OCP and corticosteroids).

Design outcomes

Primary

MeasureTime frame
Color index of melasma lesions. Timepoint: Measurement of the color index of melasma lesions at the beginning of the study (before the start of the intervention) and 4?8?12?16 weeks after the start of the use of Irsa topical product. Method of measurement: Comparing the amount of skin darkening compared to healthy skin (natural skin color 0, brief darkness 1, mild darkness 2, moderate darkness 3, severe darkness 4) by observation, photography and megometer device.

Secondary

MeasureTime frame
The extent of melasma lesions. Timepoint: Measuring the extent of melasma lesions at the beginning of the study (before the start of theintervention) and 4?8?12?16 weaks after the start of using the Irsa topica lproduct. Method of measurement: Calculating the area of the lesion using MASI score and VISIOFACE.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmasoomeh akhoondi ghahroodi

Shahed University

masoomehakhoondi3@gmail.com+98 21 4448 8342

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026